UnitedHealth Group er verdens største helsevesen-selskap, og kombinerer landets største helseforsikrer (UnitedHealthcare) med Optums helsetjenester, og nyter direkte fordeler av aldringsdynamikken i befolkningen.
UnitedHealth Group er den største helsevesen-aksjen både etter inntekt og markedsverdi, og kombinerer landets største helseforsikringsoperasjon med Optum-plattformen for helsetjenester som vokser raskt, og skaper et vertikalt integrert helsevesen som berører nesten alle aspekter av det amerikanske helsesystemet.
Data updated Feb 15 · Source: Twelve Data
UnitedHealth Group, the nation's largest health insurer and parent of Optum's healthcare services empire, has experienced a dramatic decline " down over 44% in the past year from its 52-week high of $606. The sell-off reflects a convergence of headwinds: rising medical costs, regulatory scrutiny, a DOJ investigation, and the tragic shooting of a subsidiary CEO that intensified public backlash against managed care. At a P/E of 13.2x with EPS of $22.21, the stock trades at a significant discount to historical multiples, potentially offering deep value for patient investors. The bull case centers on UNH's dominant market position in Medicare Advantage (directly benefiting from aging demographics), diversified revenue streams through Optum, and a track record of consistent earnings growth. The bear case includes elevated medical loss ratios, political risk around healthcare reform, potential regulatory actions, and questions about whether management can restore credibility. Trading well below its 50-day moving average of $321, momentum remains decidedly negative. However, UNH's structural advantages in serving an aging population and its integrated care model provide a durable competitive moat that makes this selloff worth monitoring closely.
UnitedHealth Group remains a dominant force in the healthcare sector, leveraging its integrated model of insurance (UnitedHealthcare) and health services (Optum) to drive long-term growth. The provided financial data indicates the stock is currently trading at a P/E ratio of 12.30, a valuation that appears remarkably attractive relative to historical norms for such a high-quality compounder. While the share price has retreated significantly from its 52-week high of $606.36, creating a bearish technical setup below the 50-day moving average, the company's earnings power remains resilient with an EPS of $22.21. Investors must weigh the attractive valuation against risks like regulatory scrutiny on Medicare Advantage and rising medical loss ratios. However, for value-oriented investors, UNH presents a potential opportunity to acquire a sector leader at a discounted multiple.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Hver trader har en strategi som ser flott ut i hodet deres. Backtesting er hvordan du finner ut om den faktisk fungerer. Her er hvordan du tester strategier på riktig måte, hvilke beregninger som betyr noe, og hvorfor de fleste backtestresultater er for gode til å være sant.
Powered by Rexiew